Desensitization and resensitization of β1‐ and putative β4‐adrenoceptor mediated responses occur in parallel in a rat model of cardiac failure
- 1 December 1999
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 128 (7) , 1399-1406
- https://doi.org/10.1038/sj.bjp.0702920
Abstract
Cardiostimulant effects of the non‐conventional partial agonist, CGP 12177A, are mediated by a receptor distinct from the β3‐adrenoceptor and termed the putative β4‐adrenoceptor. Using a rat model of cardiac failure, induced by myocardial infarction (MI), we compared the desensitization and resensitization of responses to CGP 12177A with those to isoprenaline and RO 363 in left (LA) and right atria (RA). We also examined the ability of β‐adrenoceptor antagonists to block responses to CGP 12177A. MI reduced the maximum inotropic response to isoprenaline by 48% (sham 4.1±0.6 mN, n=10; MI 2.1±0.4 mN, n=8, Pn=10; MI 1.8±0.3 mN, n=8, Pn=5; MI 0.7±0.2 mN, n=7, P50: sham 8.79±0.08, n=10; MI 8.30±0.10, n=8; P=0.001) and RO 363 (pEC50: sham 8.69±0.07, n=10; MI 8.33±0.10, n=8; P−1, i.p.) restored the maximum inotropic response and sensitivity to isoprenaline (sham 3.5±0.5 mN, n=9; MI 3.2±0.6 mN, n=11, P=0.702) and CGP 12177A (sham 1.6±0.3 mN, n=6; MI 1.9±0.4 mN, n=7, P=0.537) in MI animals to levels similar to those in the sham group. CGP 20712A (pKB: LA 6.7±0.2, n=6; RA 7.1±0.1, n=4), ICI 118,551 (pKB: LA 6.4±0.1, n=5; RA 6.3±0.1, n=6), propranolol (pKB: LA 6.6±0.1, n=5; RA 6.8±0.1, n=6) and bupranolol (pKB: LA 7.2±0.1, n=6; RA 7.7±0.1, n=8), showed moderate affinity for the putative β4‐adrenoceptor. Desensitization after MI and resensitization (after pertussis toxin treatment) to isoprenaline and CGP 12177A therefore occur in parallel, suggesting that the β1‐ and putative β4‐adrenoceptor use the same signalling pathway. Antagonist affinity studies confirmed that drugs acting at β1‐adrenoceptors also interact with putative β4‐adrenoceptors with approximately 100 times lower affinity. We suggest that CGP 12177A produces its cardiac effects by interacting with a low affinity state of the β1‐adrenoceptor. British Journal of Pharmacology (1999) 128, 1399–1406; doi:10.1038/sj.bjp.0702920Keywords
This publication has 31 references indexed in Scilit:
- Regulation of β-Adrenoceptors in a Rat Model of Cardiac Failure: Effect of PerindoprilJournal of Cardiovascular Pharmacology, 1998
- Validity of (−)‐[3H]‐CGP 12177A as a radioligand for the ‘putative β4‐adrenoceptor’ in rat atriumBritish Journal of Pharmacology, 1998
- Lipolytic effects of conventional β3‐adrenoceptor agonists and of CGP 12,177 in rat and human fat cells: preliminary pharmacological evidence for a putative β4‐adrenoceptorBritish Journal of Pharmacology, 1997
- Stimulation of cyclic AMP‐dependent protein kinase in rat atria by (–;)‐CGP 12177 through an atypical β‐adrenoceptorBritish Journal of Pharmacology, 1997
- Effects of (−)‐RO363 at human atrial β‐adrenoceptor subtypes, the human cloned β3‐adrenoceptor and rodent intestinal β3‐adrenoceptorsBritish Journal of Pharmacology, 1997
- Anomalous Behavior of CGP 12177A ON β2-Adrenergic ReceptorsJournal of Receptors and Signal Transduction, 1996
- Is there a third heart β-adrenoceptor?Trends in Pharmacological Sciences, 1989
- Cloning of the cDNA and Genes for the Hamster and Human β2-Adrenergic ReceptorsJournal of Receptor Research, 1988
- Mammalian .beta.2-adrenergic receptor: purification and characterizationBiochemistry, 1984
- Differentiated blockade of the chronotropic effects of various adrenergic stimuli in the cat heartLife Sciences, 1972